Resistance to non-nucleoside inhibitors of HIV-I reverse transcriptase

被引:39
作者
Bacheler, LT [1 ]
机构
[1] Dupont Merck Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA
关键词
D O I
10.1054/drup.1998.0064
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Non-nucleoside reverse transcriptase inhibitors (NNRTls) are a structurally diverse group of compounds which function as inhibitors of HIV-I replication in vitro and in vivo. Viral resistance is mediated through alterations in the amino acids which form the allosteric site on the HIV-I reverse transcriptase to which NNRTIs bind. The rapid emergence of resistant viruses has limited the utility of NNRTI monotherapy; however, recent clinical studies have shown that potent NNRTIs can contribute to profound suppression of HIV replication when used in combination therapy. An understanding of the development of resistance to NNRTIs is critical to the effective use of this class of antiretroviral agents.
引用
收藏
页码:56 / 67
页数:12
相关论文
共 98 条
[71]   HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time [J].
Perelson, AS ;
Neumann, AU ;
Markowitz, M ;
Leonard, JM ;
Ho, DD .
SCIENCE, 1996, 271 (5255) :1582-1586
[72]   Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate [J].
QuinonesMateu, ME ;
Soriano, V ;
Domingo, E ;
MenendezArias, L .
VIROLOGY, 1997, 236 (02) :364-373
[73]   The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase [J].
Rezende, LF ;
Drosopoulos, WC ;
Prasad, VR .
NUCLEIC ACIDS RESEARCH, 1998, 26 (12) :3066-3072
[74]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 MUTANTS RESISTANT TO NONNUCLEOSIDE INHIBITORS OF REVERSE-TRANSCRIPTASE ARISE IN TISSUE-CULTURE [J].
RICHMAN, D ;
SHIH, CK ;
LOWY, I ;
ROSE, J ;
PRODANOVICH, P ;
GOFF, S ;
GRIFFIN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (24) :11241-11245
[75]   NEVIRAPINE RESISTANCE MUTATIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SELECTED DURING THERAPY [J].
RICHMAN, DD ;
HAVLIR, D ;
CORBEIL, J ;
LOONEY, D ;
IGNACIO, C ;
SPECTOR, SA ;
SULLIVAN, J ;
CHEESEMAN, S ;
BARRINGER, K ;
PAULETTI, D ;
SHIH, CK ;
MYERS, M ;
GRIFFIN, J .
JOURNAL OF VIROLOGY, 1994, 68 (03) :1660-1666
[76]   NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS THAT POTENTLY AND SPECIFICALLY BLOCK HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REPLICATION [J].
ROMERO, DL ;
BUSSO, M ;
TAN, CK ;
REUSSER, F ;
PALMER, JR ;
POPPE, SM ;
ARISTOFF, PA ;
DOWNEY, KM ;
SO, AG ;
RESNICK, L ;
TARPLEY, WG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8806-8810
[77]  
RUIZ N, 1997, 4 C RETR OPP INF WAS, P206
[78]   A SHORT-TERM CLINICAL-EVALUATION OF L-697,661, A NONNUCLEOSIDE INHIBITOR OF HIV-1 REVERSE-TRANSCRIPTASE [J].
SAAG, MS ;
EMINI, EA ;
LASKIN, OL ;
DOUGLAS, J ;
LAPIDUS, WI ;
SCHLEIF, WA ;
WHITLEY, RJ ;
HILDEBRAND, C ;
BYRNES, VW ;
KAPPES, JC ;
ANDERSON, KW ;
MASSARI, FE ;
SHAW, GM .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (15) :1065-1072
[79]   2-PYRIDINONE DERIVATIVES - A NEW CLASS OF NONNUCLEOSIDE, HIV-1-SPECIFIC REVERSE-TRANSCRIPTASE INHIBITORS [J].
SAARI, WS ;
HOFFMAN, JM ;
WAI, JS ;
FISHER, TE ;
ROONEY, CS ;
SMITH, AM ;
THOMAS, CM ;
GOLDMAN, ME ;
OBRIEN, JA ;
NUNBERG, JH ;
QUINTERO, JC ;
SCHLEIF, WA ;
EMINI, EA ;
STERN, AM ;
ANDERSON, PS .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (09) :2922-2925
[80]  
SALZMAN NK, 1996, 5 WORKSH HIV DRUG RE